Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study
Blood (2023) 142 (Supplement 1): 3269.
Currently there are no citedby results. Try again later.
